ebola
viru
outbreak
western
africa
introduct
chikungunya
zika
virus
america
new
neglect
virus
continu
emerg
spread
around
world
due
lack
exist
vaccin
specif
therapeut
littl
support
care
attempt
interrupt
transmiss
provid
initi
outbreak
prompt
shift
vaccin
design
develop
identifi
novel
epitop
mechan
protect
may
offer
broader
rang
protect
group
whole
famili
virus
receptorbind
domain
motif
within
viral
envelop
protein
repres
one
excel
opportun
target
commun
epitop
share
relat
virus
similarli
virus
envelop
particip
drive
viral
egress
infect
cell
share
epitop
need
identifi
guid
develop
broadli
protect
antibodi
vaccin
discuss
recent
advanc
understand
broadli
protect
humor
respons
emerg
virus
four
epidem
foreshadow
previou
outbreak
relat
virus
demonstr
imposs
accur
predict
natur
new
epidem
prepar
made
appar
success
antibodi
ab
cocktail
zmapp
ebov
outbreak
renew
interest
antibodybas
therapeut
antivir
highlight
particular
idea
develop
broadli
protect
therapeut
would
benefici
exampl
stockpil
immunotherapeut
abl
treat
ebov
would
practic
attract
antibodi
abl
offer
protect
filovirusesparticularli
particular
speci
may
immedi
identifi
likewis
unlik
chikv
vaccin
would
deploy
en
mass
howev
employ
panalphaviru
vaccin
abl
stimul
protect
even
partial
protect
respons
multipl
pathogen
alphavirus
much
appeal
prospect
zikv
rel
neglect
mosquitoborn
flaviviru
prior
establish
foothold
brazil
like
circumst
specif
treatment
control
unstudi
viru
would
place
would
one
broadli
act
therapeut
avail
includ
panflaviviru
protect
antibodi
panflaviviru
inhibitor
nonpathogenspecif
immun
therapi
order
achiev
broadli
protect
immunotherapeut
vaccin
immunogen
novel
approach
requir
aid
identif
import
epitop
focu
discuss
recent
advanc
identif
broadli
protect
antibodi
epitop
tradit
approach
combat
viral
divers
relat
virus
exemplifi
new
tetraval
vaccin
treatment
dengu
viru
denv
infect
vaccin
provid
degre
protect
immun
infect
denv
type
inclus
four
serotyp
chimer
attenu
yellow
fever
viru
backbon
howev
protect
uniform
across
serotyp
requir
three
vaccin
across
month
limit
seen
tetraval
vaccin
suggest
complementari
approach
may
appropri
inde
recent
public
highlight
possibl
panserotyp
neutral
find
suggest
engin
singl
univers
immunogen
abl
stimul
specif
crossreact
respons
effect
use
passiv
immunotherapi
potent
broadli
neutral
monoclon
antibodi
mab
may
possibl
thu
denv
held
model
develop
optim
novel
therapeut
vaccin
new
emerg
virus
denv
belong
flaviviru
genu
includ
west
nile
viru
wnv
yellow
fever
viru
zikv
sever
virus
may
caus
enceph
flavivirus
complex
quaternari
structur
adopt
differ
morpholog
temperatur
shift
furthermor
virus
undergo
seri
complex
rearrang
surfac
glycoprotein
gp
viru
matur
viru
assemblybud
endoplasm
reticulum
viral
entri
acidifi
endosom
flavivirus
consist
premembran
prm
envelop
e
protein
associ
give
total
trimer
spike
immatur
viru
prm
act
chaperon
sit
fusion
loop
e
prevent
prematur
trigger
virion
exit
cell
prm
proteolyt
process
allow
e
protein
rearrang
headtotail
homodim
convers
viral
entri
follow
absorpt
cell
mediat
domain
iii
e
protein
flavivirus
endocytos
traffic
acidifi
endosom
e
homodim
trigger
low
ph
rearrang
homotrim
expos
hydrophob
fusion
loop
domain
ii
e
protein
drive
membran
fusion
viral
entri
primari
humor
immun
respons
denv
domin
antibodi
target
prm
domain
ii
e
mani
antibodi
crossreact
bind
multipl
denv
serotyp
howev
repres
broadli
protect
respons
lack
neutral
potenc
possess
abil
promot
antibodydepend
enhanc
ade
contrast
domain
iii
e
ediii
specif
antibodi
constitut
minor
compon
overal
human
humor
respons
may
potent
neutral
recent
robinson
et
al
use
structureguid
design
optim
exist
ediii
antibodi
start
potent
mab
target
conserv
epitop
within
denv
ediii
network
map
individu
interact
paratop
epitop
built
experiment
mutat
paratop
particular
within
complementaritydetermin
region
cdr
follow
structur
analysi
antibodi
optim
maxim
affin
gave
rise
potent
panserotyp
mab
neutral
four
serotyp
reduc
virusenhanc
activ
compar
parent
antibodi
importantli
use
therapeut
effect
anim
model
denv
pathogenesi
studi
offer
excit
roadmap
care
craft
paratop
epitop
interact
use
structureguid
design
maxim
affin
also
broaden
specif
studi
critic
highresolut
structur
viral
particl
andor
envelop
protein
nativ
conform
also
help
extens
map
antibodyaccess
envelop
surfac
larg
panel
mab
complex
quaternari
epitop
target
neutral
antibodi
nab
prevent
flaviviru
entri
exampl
recent
report
studi
potent
mab
describ
epitop
span
three
separ
e
protein
monom
virion
mab
epitop
lock
multipl
import
domain
e
protein
place
thu
prevent
conform
rearrang
also
requir
fab
fragment
fulli
coat
viru
surfac
due
uniqu
footprint
due
complex
quaternari
structur
target
mab
major
serotyp
specif
howev
recent
report
dejnirattisai
et
al
describ
isol
broadli
neutral
antibodi
denv
base
complex
highli
organ
structur
e
protein
mab
shown
target
epitop
span
e
protein
e
protein
dimer
partial
matur
virusan
epitop
resembl
bind
site
prm
antibodi
e
dimer
epitop
ede
broadli
neutral
across
dengu
serotyp
suggest
epitop
may
make
ideal
immunogen
stimul
broad
protect
respons
fusion
loop
flavivirus
rel
conserv
antibodi
target
fusion
loop
epitop
fle
gener
crossreact
abl
neutral
differ
flavivirus
flespecif
antibodi
usual
lower
neutral
capac
demonstr
higher
ade
edespecif
antibodi
flespecif
crossneutr
antibodi
neutral
zikv
provid
vivo
protect
zikv
structur
zikv
e
protein
complex
indic
antibodi
bind
immatur
partial
immatur
viru
particl
fulli
matur
viru
particl
fusion
loop
buri
compact
edim
arrang
interestingli
analysi
cryoelectron
microscopi
cryoem
structur
zikv
suggest
zikv
particl
thermal
stabl
larg
present
matur
form
interest
solv
structur
zikv
viru
particl
complex
order
reveal
flespecif
antibodi
neutral
zikv
similarli
flavivirus
alphaviru
envelop
glycoprotein
form
icosahedr
structur
total
copi
heterodim
assembl
spike
virion
surfac
class
ii
membran
fusion
protein
sit
base
trimer
spike
posit
top
fusion
loop
locat
distal
end
domain
ii
protect
domain
b
neutral
ph
domain
locat
center
spike
surfac
possess
put
receptor
bind
site
acidifi
endosom
low
ph
trigger
conform
rearrang
envelop
glycoprotein
domain
b
dissoci
tip
domain
ii
expos
fusion
loop
form
homotrim
expos
fusion
loop
viru
fusion
endosom
membran
analog
conformationdepend
antiflaviviru
mab
other
describ
similar
epitop
alphavirus
target
complex
quaternari
epitop
bridg
domain
prevent
lowphinduc
conform
chang
thu
virus
class
ii
membran
fusion
protein
develop
domainspan
antibodi
may
highli
effect
method
protect
use
singleparticl
cryoem
identifi
epitop
span
domain
domain
b
two
separ
glycoprotein
within
one
viral
spike
chikv
particl
similarli
studi
antialphaviru
mab
shown
bridg
domain
b
within
glycoprotein
crosslink
protein
neighbor
spike
mab
epitop
act
lock
conform
matur
glycoprotein
place
crosslink
domain
thu
prevent
lowphtrigg
conform
rearrang
requir
expos
fusion
loop
interestingli
panel
mous
mab
broad
specif
multipl
alphavirus
recent
identifi
crossreact
mab
bind
conserv
epitop
domain
b
caus
conform
rearrang
reposit
domain
enabl
crosslink
two
molecul
neighbor
spike
epitop
target
mab
conserv
across
arthritogen
alphavirus
led
broad
inhibit
multipl
alphavirus
panel
result
studi
suggest
conserv
b
domain
antigen
determin
could
target
multipl
alphavirus
global
concern
vaccin
antibodi
therapeut
develop
besid
flavivirus
alphavirus
anoth
major
focu
emerg
viru
research
humor
respons
ebov
filovirus
mani
descript
potent
neutral
mab
effect
immunogen
invok
protect
respons
publish
recent
studi
describ
includ
sever
attempt
identifi
novel
mab
epitop
abl
effect
neutral
five
ebovlik
speci
even
distantli
relat
filovirus
result
analys
antibodi
emphas
possibl
pathway
achiev
broadli
neutral
antibodi
particular
receptorbind
site
rb
virus
rel
conserv
due
requir
engag
host
cell
target
inde
filovirus
includ
divers
lloviu
virus
llov
util
receptor
niemannpick
viral
entri
result
attract
target
panfiloviru
protect
respons
antibodi
cocktail
use
passiv
immunotherapi
howev
protect
potenti
achil
heel
ebov
filovirus
occlud
conserv
rb
sever
unusu
way
first
ebov
glycoprotein
gp
open
read
frame
actual
encod
nonstructur
secret
protein
term
sgp
cotranscript
edit
event
requir
give
rise
fulllength
membranebound
gp
hypothes
secret
larg
amount
sgp
act
immunolog
decoy
lead
poor
neutral
respons
second
membran
distal
region
gp
associ
extens
nand
olink
glycosyl
thu
act
immunodomin
domain
requir
function
gp
final
follow
attach
endocytosi
viru
traffick
acidifi
endosom
unlik
mani
virus
requir
endocytosi
ebov
directli
ph
depend
rather
gp
requir
proteolyt
activ
phdepend
host
cell
proteas
order
remov
glycosyl
membran
distal
domain
expos
rb
rb
engag
cholesterol
transport
found
late
endosom
membran
unusu
mechan
expos
rb
within
endosom
like
help
protect
viru
neutral
antibodi
target
conserv
region
crystal
structur
proteolyt
process
gp
complex
demonstr
twostep
process
engag
hydrophob
trough
prime
gp
lead
conform
rearrang
requir
drive
membran
fusion
hydrophob
domain
head
prime
gp
highli
conserv
across
filoviru
famili
mab
direct
caviti
broadli
neutral
filovirus
although
potenc
vari
thu
domain
highli
attract
immunogen
potent
panfiloviru
respons
major
mab
epitop
describ
reli
vitro
measur
effici
canon
antivir
mechan
antibodi
neutral
viru
entri
analysi
mechan
tradit
serv
criterion
antivir
antibodi
select
howev
mani
virus
vitro
potenc
alway
equat
protect
vivo
function
activ
inde
demonstr
vivo
antibodi
addit
neutral
mani
factor
involv
antibodi
control
acut
viral
infect
includ
complement
mechan
target
infect
cell
well
antibodi
target
specif
pathogen
function
antidenv
mab
thank
advanc
variou
techniqu
includ
singleparticl
cryoem
highthroughput
antibodi
repertoir
sequenc
b
cell
clone
understand
detail
entryblock
mechan
neutral
antibodi
almost
viru
famili
inhibit
receptor
bind
prevent
conform
chang
within
fusion
protein
greatli
improv
discuss
knowledg
garner
mechanist
studi
success
guid
therapeut
antibodi
vaccin
design
recent
studi
mode
action
panel
human
mous
mab
target
chikv
glycoprotein
discov
novel
antivir
mechan
addit
classic
neutral
viru
entri
postentri
addit
mab
chikvinfect
cell
inhibit
chikv
releas
via
bival
bind
contrast
viru
entri
neutral
monoval
fab
fragment
mab
demonstr
inhibit
viral
releas
two
human
mab
target
chikv
domain
panel
mous
mab
target
epitop
within
domain
b
describ
domain
b
mab
broadli
activ
arthritogen
alphavirus
nonneutr
mab
target
chikv
iii
also
report
inhibit
chikv
releas
structur
studi
human
mabtreat
chikvinfect
cell
reveal
block
membran
curvatur
format
crosslink
mab
lead
arrest
assembl
nucleocapsid
core
beneath
plasma
membran
j
jin
g
simmon
unpublish
data
suggest
later
organ
viral
spike
provid
pull
forc
chikv
bud
disrupt
mab
crosslink
fig
mechan
differ
previous
report
mechan
seen
antibodi
abl
block
viral
egress
exampl
antibodi
target
influenza
viru
neuraminidas
activ
requir
viral
releas
nonneutr
antibodi
target
matrix
protein
also
inhibit
viral
egress
possibl
interf
virion
assembl
bud
led
develop
matrix
protein
possibl
vaccin
candid
two
nonneutr
marburg
viru
glycoproteinspecif
mab
report
prevent
viru
releas
induc
aggreg
progeni
viru
particl
cell
surfac
interest
discov
chikv
nab
target
differ
domain
crosslink
glycoprotein
plasma
membran
order
disrupt
critic
glycoprotein
organ
requir
membran
bend
exampl
identif
bud
specif
epitop
would
aid
design
therapeut
antibodi
vaccin
immunogen
alphavirus
manner
similar
seen
epitop
critic
viral
entri
phenotyp
inhibit
viral
releas
mab
also
observ
virus
viral
famili
alphavirus
includ
bovin
leukemia
viru
herpesviru
vaccinia
viru
rubella
viru
mechan
resolv
report
phenotyp
would
interest
determin
whether
glycoprotein
crosslink
mab
block
viral
bud
virus
need
glycoprotein
drive
membran
curvatur
format
novel
therapeut
prophylact
answer
requir
order
combat
plethora
emerg
reemerg
pathogen
fortun
identif
innov
target
viral
pathway
reveal
new
way
gain
humor
protect
togeth
novel
method
optim
specif
target
immunotherapeut
vaccin
immunogen
arsen
broadli
protect
measur
built
emerg
virus
work
includ
effort
jing
jin
graham
simmon
fund
hh
nih
nation
institut
allergi
infecti
diseas
niaid
